Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

a rodent model;

-- Silencing of KSP mRNA in vivo by greater than 50 percent after a single injection of a KSP-specific siRNA in a rodent model; and

-- Halting of human cancer cell proliferation in vitro when KSP was silenced by a target-specific siRNA.

Alnylam's RNAi therapeutic, ALN-VSP01, is comprised of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi. Each siRNA targets a distinct and well-validated gene in the growth and proliferation of tumors: VEGF, a key mediator of tumor angiogenesis; and KSP, a protein required for cell division that, when inhibited, leads to cell arrest and cell death in dividing cells. ALN-VSP01 is formulated using Alnylam's novel liposomal formulation technology, which has been used to achieve delivery of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal delivery can also be optimized for delivery to other organs and tumor types, such that ALN-VSP01 may ultimately have potential for a range of solid tumors. Alnylam's collaborator, Inex Pharmaceuticals Corporation, is manufacturing the lipid-based formulation as the company prepares for pre-IND toxicology studies with ALN-VSP01.

"Despite many advances in the treatment of cancer with targeted small molecules and antibody therapeutics, the clinical impact of these therapies is generally measured in only months of survival benefit. New modalities like RNAi therapeutics offer the potential to advance cancer therapy to a whole new level," said George D. Demetri, M.D., of Dana-Farber Cancer Institute and Harvard Medical School. "I'm encouraged by Alnylam's pre-clinical data demonstrating the ability to silence disease pathway genes with delivery of RNAi therapeutics, and believe that the application of this approach for the treatment of primary and secondary liver cancers holds considerable promise."

About Liver Cancer

Primary liver cancer is cancer that forms in the tissues of the l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... 27, 2015 Kalorama Information expects the ... (EMR) to grow well past the period where ... to a recent report.  The healthcare market research ... continued efficiency improvements will grow the market seven ... five years.  The market for EMR systems continues ...
(Date:4/27/2015)... 2015  Novira Therapeutics, Inc., a privately held, clinical-stage ... chronic hepatitis B virus (HBV) infection, today announced the ... core inhibitor candidate, NVR 3-778, at the 2015 annual ... the Liver (EASL) in Vienna, Austria ... from studies performed in a humanized UPA/SCID mouse model ...
Breaking Medicine Technology:Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 17, 2011 Damage to the spine can happen for ... car accident, wear and tear from old age, or blunt ... past have had to deal with back braces, reduced mobility, ... Seyed M. Rezaian,s patented Spinal Fixator, patients are able to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... Deputy Secretary of the U.S. Department of Agriculture, for a ... at its facility in York, Pennsylvania. The White ... direction of President Obama. The Winning the Future Roundtables ...
Cached Medicine Technology:Dr. Seyed M. Rezaian's Spinal Fixator a Revolutionary Invention for Healing Injuries of the Thoracolumbar Spine 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:4/27/2015)... 27, 2015 Women may have a ... according to a new study published online in the ... brain injury (MTBI), is a common medical problem affecting ... , In most cases, patients who experience MTBI ... 15 percent of MTBI patients will continue to experience ...
(Date:4/27/2015)... Moreno Ranches, a producer of Brahman ... to announce their "This is It" educational Brahman cattle ... breeding and education was a huge success. The educational ... 2015. It brought together youth, educators, and experts ... breeding in general, and Brahman cattle breeding in particular. ...
(Date:4/27/2015)... April 27, 2015 UC Davis ... molecular basis of an inherited disorder that historically ... also arises in other populations of Semitic descent, ... series of elegant experiments, the researchers uncovered the ... leukodystrophy that is an incurable and progressively fatal ...
(Date:4/27/2015)... April 27, 2015 On May 5, people ... ask their social media friends around the world to join ... asthma. , May 5 is World Pulmonary Hypertension Day ... leader in the global PH community, will take part in ... blood pressure of the lungs. PH is an increase in ...
(Date:4/27/2015)... Array Health , a leading provider ... Lance Hood, senior director of marketing, will participate in ... Health Care Marketing Summit on April 29, 2015. ... Director of Payer Services, Leavitt Partners, LLC, will address ... a retail/e-commerce perspective – and equip attendees with the ...
Breaking Medicine News(10 mins):Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3Health News:Leading Ranch for Brahman Cattle for Sale, Moreno Ranches, Announces Conclusion of 'This is It' Event for Brahman Juniors. 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 2Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 3Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2
... life when some students pushed him from the front bench in ... ,Qamar Irfan, a Class 5 student of Sarda Convent School in ... forcibly pushed off the bench by students in a fight over ... members, Qamar rushed into the class as soon as school opened ...
... diagnosed with stomach cancer. He was 68 years old then.// ... out that the hospital pathologist had misdiagnosed tests and Mr. ... out in October 2002 at Walsall Manor Hospital. The pathologist ... Wolverhampton trust. Royal Wolverhampton Hospitals NHS Trust owned up liability ...
... who are circumcised are less likely to contract HIV ... research presented recently at the International AIDS Conference at ... percent less likely to contract HIV than their uncircumcised ... ,Circumcision is the surgical removal of the foreskin ...
... New York shows that patients, who experience the health ... //be a lot done for its improvement, with almost ... health care. ,According to the ... Performance Health System, an astonishingly high amount of Americans, ...
... According to a new study by Duke University Medical ... the rate of treatment //for chronic hepatitis C than ... in the August issue of Gastroenterology, which is the ... (AGA), that the African American patients with hepatitis C ...
... The Health Service Executive in Ireland is all set to ... emergency overcrowding.// ,The Irish Examiner reports that hospitals may ... with the A&E crisis, where patients are made to wait ... A&E patients are not made to wait over 24 hours. ...
Cached Medicine News:Health News:Majority Of People In US Seek Essential Changes In Health Care System 2Health News:Majority Of People In US Seek Essential Changes In Health Care System 3Health News:Majority Of People In US Seek Essential Changes In Health Care System 4Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 2Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 3
IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
... RSV Test utilizes a new, improved format that ... rapid RSV detection. The testing device employs innovative ... reagents have already been applied to the testing ... with clear-cut results shown by the appearance of ...
Latex agglutination slide test for the qualitative detection of rotavirus from fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: